Nachrichten zur Sarepta Therapeutics Aktie

The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron

Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron are included in this Analyst Blog.…

Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?

Its always tough to be compared to a giant.…

Sarepta Therapeutics: Leading The Way In DMD Treatment With Gene Therapy Innovations

…

Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today

One pundit feels there is solid potential in one of the companys more recently approved drugs.…

Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval

…

Sarepta Therapeutics (SRPT) Surges 16.7%: Is This an Indication of Further Gains?

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions…

Sarepta Therapeutics shares rally, Mizuho says confidence in label expansion remains unwavering By Investing.com

Sarepta Therapeutics shares rally, Mizuho says confidence in label expansion remains unwavering…

Sarepta Therapeutics provides Q4 and FY forecast

…

Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?

Both develop medicines for rare diseases, and each aims to conquer a niche market.…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

SRPT LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Sarepta Therapeutics: Strong Q3 Earnings Help Offset Overblown Clinical Data Concerns

…

Is Sarepta Therapeutics Stock a Bad-News Buy?

Analysts still expect some sizable returns from the stock.…

Is Sarepta Therapeutics Stock a Bad-News Buy? @themotleyfool #stocks $SRPT

Analysts still expect some sizable returns from the stock.…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript

SRPT earnings call for the period ending September 30, 2023.…

SRPT INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues…

Sarepta Therapeutics, Inc. (SRPT) Q3 2023 Earnings Call Transcript

…

Sarepta Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Sarepta Therapeutics GAAP EPS of -$0.46 beats by $0.80, revenue of $331.8M beats by $45.03M

…

Sarepta Therapeutics Q3 2023 Earnings Preview

…

Sarepta Therapeutics, Petmed Express among healthcare movers

…

Sarepta Therapeutics crushed after EMBARK misses primary endpoint, promoting 2 downgrades By Investing.com

Sarepta Therapeutics crushed after EMBARK misses primary endpoint, promoting 2 downgrades…

: Sarepta Therapeutics shares plunge as gene therapy trial falls short of primary goal

Company plans to seek label expansion for Duchenne muscular dystrophy treatment…

How to Invest in Genetics (Updated 2023)

Genetics is the study of genes, their variations and hereditary characteristics, as well as how these traits are passed on…

Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy

…

Oligonucleotide API Market revenue to surpass USD 5 Billion by 2035, says Research Nester

Major Oligonucleotide API Market players include Ionis Pharmaceuticals, Inc., Jazz Pharmaceuticals plc, Biogen Inc., Sarepta Therapeutics, Alnylam Pharmaceuticals, Inc., Corden…

Is Sarepta Therapeutics Stock a Top Growth Vehicle?

An upcoming data readout could fuel another rally in the biotechs shares....…

Insiderhandel: Aufsichtsrat kauft Aktien von Sarepta Therapeutics im Wert von 1.092.429$

Chambers, Michael Andrew - Aufsichtsrat - Tag der Transaktion: 2023-08-14...…

Insiderhandel: Aufsichtsrat kauft Aktien von Sarepta Therapeutics im Wert von 2.559.272$

Chambers, Michael Andrew - Aufsichtsrat - Tag der Transaktion: 2023-08-11...…

Insiderhandel: Aufsichtsrat kauft Aktien von Sarepta Therapeutics im Wert von 3.701.067$

Chambers, Michael Andrew - Aufsichtsrat - Tag der Transaktion: 2023-08-10...…

Insiderhandel: Aufsichtsrat verkauft Aktien von Sarepta Therapeutics im Wert von 1.600.800$

Wigzell, Hans Lennart Rudolf - Aufsichtsrat - Tag der Transaktion: 2023-08-04...…

Sarepta Therapeutics (SRPT) Q2 2023 Earnings Call Transcript

SRPT earnings call for the period ending June 30, 2023....…

Sarepta Therapeutics (SRPT) Reports Q2 Loss, Misses Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 85.71% and 1.21%, respectively, for the quarter ended June 2023. Do…

Sarepta Therapeutics Q2 Loss Decreases, beats estimates

WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT) revealed Loss for second quarter that decreased from the same period last year and…

Sarepta (SRPT) Sells Priority Review Voucher for $102M

Sarepta (SRPT) sells its priority review voucher that was awarded following the FDAs approval to Elevidys gene therapy for treating…

Sarepta raises $102M from selling priority review voucher

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sarepta Therapeutics completes sale of priority review voucher for $102 million

Sarepta Therapeutics Inc. SRPT said Wednesday it has completed the sale of its Rare Pediatric Disease Priority Review Voucher for…

Sarepta slumps as concerns emerge around upcoming gene therapy data

...June 23 (Reuters) - Sarepta Therapeutics shares slumped 11% on Friday......…

What 25 Analyst Ratings Have To Say About Sarepta Therapeutics

Latest Ratings for SRPT DateFirmActionFromTo Mar 2022Morgan StanleyMaintainsEqual-Weight Mar 2022RBC CapitalMaintainsOutperform Feb 2022Morgan StanleyMaintainsEqual-Weight View…

FDA OKs Elevidys As First Gene Therapy To Treat Duchenne Muscular Dystrophy

WASHINGTON (dpa-AFX) - Sarepta Therapeutics, Inc. announced Friday that the U.S. Food and Drug Administration or FDA has accelerated approval…

FDA OKs Elevidys As First Gene Therapy To Treat Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc. announced Friday that the U.S. Food and Drug Administration or FDA has accelerated approval of ELEVIDYS (delandistrogene…

Sarepta Therapeutics downgraded at Evercore ISI after FDA approval of gene therapy

Sarepta Therapeutics Inc. SRPT , which yesterday scored a win with U.S. Food and Drug Administration approval of the first…

Roche-Partner Sarepta erhält US-Zulassung für DMD-Therapie

Pharma - Der amerikanische Lizenzpartner von Roche, Sarepta, hat von der Gesundheitsbehörde FDA die Zulassung für seine Gentherapie Elevidys in…

The Price of First Gene Therapy for Muscular Dystrophy: $3.2 Million

The drug, from Sarepta Therapeutics, promises to repair the defective gene at the root of the fatal disorder, but is…

Form 8-K Sarepta Therapeutics, For: Jun 22

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

XFRA : AB3A: Wiederaufnahme/Resumption

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…

Sarepta gets FDA approval for rare genetic disorder treatment

Sarepta Therapeutics Inc. SRPT said Thursday that the Food and Drug Administration approved its Elevidys gene therapy to treat the…

XFRA : INSTRUMENT_SUSPENSION - US8036071004

Instrument ID [10661] (AB3A - US8036071004) suspended...…